An investigator is recruiting subjects for a study of a new antidepressant drug. The investigator has targeted a population of patients who might clearly benefit but who are also institutionalized for a variety of psychiatric conditions. The patients are in a controlled environment and it is believed there would be little problem recruiting subjects for the study. Which of the following issues of vulnerability should be of most concern to the IRB?A. The patients have clinical depression which is a difficult disease to treat.B. The patients are institutionalized.C. The patients are probably illiterate.D. The patients may have experience participating in research.

Quesiton : An investigator is recruiting subjects for a study of a new antidepressant drug. The investigator has targeted a population of patients who might clearly benefit but who are also institutionalized for a variety of psychiatric conditions. The patients are in a controlled environment and it is believed there would be little problem recruiting subjects for the study. Which of the following issues of vulnerability should be of most concern to the IRB?A. The patients have clinical depression which is a difficult disease to treat.B. The patients are institutionalized.C. The patients are probably illiterate.D. The patients may have experience participating in research.

Answer: B. The patients are institutionalized.

An investigator is recruiting subjects for a study of a new antidepressant drug. The investigator has targeted a population of patients who might clearly benefit but who are also institutionalized for a variety of psychiatric conditions. The patients are in a controlled environment and it is believed there would be little problem recruiting subjects for the study. Which of the following issues of vulnerability should be of most concern to the IRB?A. The patients have clinical depression which is a difficult disease to treat.B. The patients are institutionalized.C. The patients are probably illiterate.D. The patients may have experience participating in research. The patients are in a controlled environment and it is believed there would be little problem recruiting subjects for the study . Which of the following issues of vulnerability should be of most concern to the IRB? A . The patients have clinical depression which is a difficult disease to treat. B . The patients are institutionalized. C . While the study is ongoing a new drug becomes commercially available that may have equal or greater benefit to the subject. The investigator should do which of the following ? Discuss the pros and cons of both the investigational drug and the commercially available drug and then allow the subject to decide whether to withdraw from the research ... View Topics View Topics In a clinical study for a new antidepressant drug the nurse was asked to select patients for the study . Which parameters should the nurse assess to include the patient in the study ? Select all that apply. 4. Cortisol levels in urine Corticotrophin-releasing hormone Blood pressure Serotonin levels Urine output and fluid intake 1 Correct 2 Correct 3 Incorrect 4 Correct 5 ... Conducting Outpatient and Inpatient Clinical Research Using Legend or Investigational New Drugs ... Investigator Dispensing and Study Drug Management Requirements. A. Maintaining a Drug Accountability Record. The investigator must maintain records of the product's delivery to the study site the inventory at the site the use by each subject ... that the clinical investigator has or may have (i.e. for up to 1 year following conclusion of the clinical study ) in the investigational drug or the company that owns the drug being evaluated under the IND application; or (2) compensation received by the clinical investigator that is explicitly greater for a favorable clinical study outcome ... Practice Problems: ANOVA. A research study was conducted to examine the clinical efficacy of a new antidepressant . Depressed patients were randomly assigned to one of three groups: a placebo group a group that received a low dose of the drug and a group that received a moderate dose of the drug. Mon Sep 14 2009 00:00:00 GMT+0530 (IST) · Clinical Study to Test a New Drug to Treat Major Depression (PKI113009) ... placebo controlled exploratory adaptive design study the antidepressant and plasma cytokine lowering effects of the GW856553 will be investigated in adult subjects diagnosed with MDD. ... To learn more about this study you or your doctor may contact the study ... The IB also provides insight to support the clinical management of the study subjects during the course of the clinical trial. ... 7.3 Contents of the Investigator's Brochure The IB should contain the following sections each with literature references where appropriate: ... Guidance should also be provided to the clinical investigator on the ... Mon Mar 12 2018 00:00:00 GMT+0530 (IST) · One of your subjects is half way through a study of an investigational antidepressant that is injected weekly. the drug requires a taper-down regimen that is it should not be stopped abruptly. you learn that the subject will be admitted to prison next week prior to the next scheduled injection. what is the appropriate response for the researcher? the researcher should contact the judge in ... To interpret a trial that does not distinguish a new drug from an active comparator drug one has to know that the patients assigned to the old drug would have been different (i.e. worse) had they not been treated with the old drug in this particular experiment.